Cellulitis and Abscess Management in the Era of Resistance to Antibiotics (CAMERA) Appendix F. Chart Audit InstrumentI. Patient Demographic InformationAge (years): _________ (if <1, Enter 0)Gender__ 1 Male__ 2 FemaleRace(check all that apply) __ 1 American Indian / Alaska Native__ 2 Asian__ 3 Native Hawaiian or Other Pacific Islander__ 4 Black or African American__ 5 White__ 6 UnknownEthnicity__ 1 Hispanic or Latino__ 2 Not Hispanic or Latino__ 3 UnknownInsurance Status (check all that apply)__ 1 Private or Managed Care__ 2 Medicare__ 3 Medicaid__ 4 No Insurance / Self Pay__ 5 UnknownII. Visit Information — Reason for Visit:Visit Date (MM/YYYY): ___ ___/20___ ___Documented Risk Factors(check all that apply)__ 1 Recent hospitalization (within 1 month)__ 2 Family member within (last 6 months)__ 3 Sport team: ______________________________ 4 History of MRSA: ____________________ 5 Eczema__ 6Other skin condition: ________________________ 7 Immunocompromized (Cancer, HIV, chronic oral steroid use, or described as immunocompromized)__ 8 Diabetes__ 9 NoneFever:a. History of fever: __ 1 Yes __ 0 No b. Visit temperature ______° __ 1 C __ 2 FNumber of skin or soft tissue lesions: ______a. Describe if no number given.Description of the largest lesion: a. Location: _________________(face, neck, trunk, arm, hand, buttock, leg, foot, head, elsewhere)Description of largest site continued:b. Size: __ 1 < 1 cm __ 2 1-5 cm __ 3 > 5 cm __ 4 Unknown/not documented in chart YesNoNo Mentionc. Red (erythema)107d. Swollen (edema)107e. Warm107f. Painful/Tender107g. Fluctuant, yellow or white center, central point or “head” (induration)107h. Draining Pus (discharge, purulent)107Incision and Drainage(check all that apply)__ 1 Incision and Drainage__ 2 Needle Aspiration__ 3 Referred__ 4 Manually Expressed__ 5 Packed__ 6 Not performed III. Treatment and Follow-upCulture —review the chart for:__ 1 Obtained__ 0 Not ObtainedIf culture was obtained, which of the following was documented (Check all that apply)__ 1 Final Culture Result:___________________ 2 Patient Notification__ 3 New Prescription, specifiy:__________________ 0 Not documented in chartAntibiotic Initially Prescribed: __ 1 Yes↓ __ 0 No 1a. If Yes, name(s): _________________________Initial Antibiotic justification:__ 1 Empiric for suspected MRSA__ 2 Empiric for non-MRSA or Streptococcus__ 3 Other, specify: _________________________ 0 NoneScheduled patient follow-up__ 1 PRN (as needed)__ 2 Return to clinic scheduled__ 0 NonePatient education (Check all that apply)__ 1 Documented reasons to follow-up__ 2 Patient hand-out__ 3 Verbal teaching__ 0 NoneIV. Diagnoses and Billing Codes1. All ICD-9 Codes for the Visit:a. ___________b. ___________c. ___________d. ___________e. ___________2. All CPT Codes for the Visit:a. ___________b. ___________c. ___________d. ___________e. ___________V. Subsequent Office Care (next 14 days) and Patient OutcomesA. Subsequent Office Care:Number of return office visits for the same infection(s): _______Any additional procedures in the office:If YES, complete section VI← __ 1 Yes↓ __ 0 NoChange in Antibiotic: __ 1 Yes __ 0 No 3a. If Yes, name(s):_________________________Emergency department / urgent care visit: __ 1 Yes __ 0 NoHospitalization: __ 1 Yes __ 0 NoB. Patient-reported Outcomes:Type of report: __ 1 Diary __ 2 Telephone Survey __ 0 None → (STOP, end of audit)Number of days until resolution of fever: ____Number of days until resolution of infection: ____Reported antibiotic change: __ 1 Yes↓ __ 0 No 4a. If Yes, name(s):_________________________Reported Emergency Department Visit: __ 1 Yes __ 0 NoReported Hospitalization: __ 1 Yes __ 0 No VI. Subsequent Visit Information (only answer the following sections if question V.A2. is “YES”)Visit Date (MM/YYYY): ___ ___/20___ ___Documented Risk Factors(check all that apply)__ 1 Recent hospitalization (within 1 month)__ 2 Family member within (last 6 months)__ 3 Sport team: ______________________________ 4 History of MRSA: ____________________ 5 Eczema__ 6Other skin condition: ________________________ 7 Immunocompromized (Cancer, HIV, chronic oral steroid use, or described as immunocompromized)__ 8 Diabetes__ 9 NoneFever: a. History of fever: __ 1 Yes __ 0 No b. Visit temperature ______° __ 1 C __ 2 FNumber of skin or soft tissue lesions: ______Description of the largest lesion:a. Location: _________________(face, neck, trunk, arm, hand, buttock, leg, foot, head, elsewhere)Description of largest site continued:b. Size: __ 1 < 1 cm __ 2 1-5 cm __ 3 > 5 cm __ 4 Unknown/not documented in chart YesNoNo Mentionc. Red (erythema)107d. Swollen (edema)107e. Warm107f. Painful/Tender107g. Fluctuant, yellow or white center, central point or “head” (induration)107h. Draining Pus (discharge, purulent)107Incision and Drainage(check all that apply)__ 1 Incision and Drainage__ 2 Needle Aspiration__ 3 Referred__ 4 Manually Expressed__ 5 Packed__ 6 Not performed VII. Subsequent Treatment and Follow-upCulture —review the chart for:__ 1 Obtained__ 0 Not ObtainedIf culture was obtained, which of the following was documented (Check all that apply)__ 1 Final Culture Result:___________________ 2 Patient Notification__ 3 New Prescription, specifiy:__________________ 0 Not documented in chartAntibiotic Prescribed: __ 1 Yes __ 0 No 1a. If Yes, name(s):_________________________Antibiotic justification:__ 1 Empiric for suspected MRSA__ 2 Empiric for non-MRSA or Streptococcus__ 3 Other, specify:_________________________ 0 NoneScheduled patient follow-up__ 1 PRN (as needed)__ 2 Return to clinic scheduled__ 0 NonePatient education (Check all that apply)__ 1 Documented reasons to follow-up__ 2 Patient hand-out__ 3 Verbal teaching__ 0 NoneVIII. Subsequent Diagnoses and Billing Codes1. All ICD-9 Codes for the Visit:a. ___________b. ___________c. ___________d. ___________e. ___________2. All CPT Codes for the Visit:a. ___________b. ___________c. ___________d. ___________e. ___________Return to Contents Current as of March 2011 Internet Citation: Cellulitis and Abscess Management in the Era of Resistance to Antibiotics (CAMERA). March 2011. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/research/findings/final-reports/mrsa/nc_mrsaapf.html